Pathological features of glycogen storage disease type II highlighted in the knockout mouse model
- PMID: 10547605
- DOI: 10.1002/(SICI)1096-9896(199911)189:3<416::AID-PATH445>3.0.CO;2-6
Pathological features of glycogen storage disease type II highlighted in the knockout mouse model
Abstract
Glycogen storage disease type II (GSDII; Pompe's disease) is an autosomal recessive disease caused by lysosomal alpha-glucosidase deficiency. Skeletal muscle weakness is the most conspicuous clinical symptom of patients suffering from GSDII and skeletal muscle also is prominently involved in the knockout mouse model of this disease. Thus far, however, little detailed information has been published on the pathological changes in other mouse tissues. This paper aims to provide these data and gives a record of the clinical course of the mouse model over a 2-year period. Four-month-old affected mice perform worse in a running wheel than their unaffected littermates, but do not yet display other clear signs of disease. The lysosomal glycogen storage, already evident at birth, becomes more severe in time, leading to muscle wasting by 9-10 months of age and then limb girdle weakness and kyphosis. The disease does not markedly shorten the animal's life span despite the serious tissue pathology, which is not limited to heart and skeletal muscle, but is also seen in the smooth muscle of blood vessels and of the respiratory, digestive, and urogenital tracts. In addition, the mice have lysosomal glycogen storage in the liver, kidney, spleen, and salivary gland; in Schwann cells of the peripheral nerves, and in a subset of neurons in the central nervous system. By pathological criteria, the knockout mouse model parallels the human infantile form of GSDII and is attractive for studying the possible reversal of tissue pathology and symptomatology under different therapeutic regimes.
Copyright 1999 John Wiley & Sons, Ltd.
Similar articles
-
Morphological changes in muscle tissue of patients with infantile Pompe's disease receiving enzyme replacement therapy.Muscle Nerve. 2003 Jun;27(6):743-51. doi: 10.1002/mus.10381. Muscle Nerve. 2003. PMID: 12766987
-
Rescue of enzyme deficiency in embryonic diaphragm in a mouse model of metabolic myopathy: Pompe disease.Development. 2004 Jun;131(12):3007-19. doi: 10.1242/dev.01169. Development. 2004. PMID: 15169761
-
Hearing loss in infantile Pompe's disease and determination of underlying pathology in the knockout mouse.Neurobiol Dis. 2004 Jun;16(1):14-20. doi: 10.1016/j.nbd.2003.12.018. Neurobiol Dis. 2004. PMID: 15207257
-
Pompe disease (glycogen storage disease type II): clinical features and enzyme replacement therapy.Acta Neurol Belg. 2006 Jun;106(2):82-6. Acta Neurol Belg. 2006. PMID: 16898258 Review.
-
[Pompe's disease. Part I: pathogenesis and clinical features].Ideggyogy Sz. 2009 Jul 30;62(7-8):231-43. Ideggyogy Sz. 2009. PMID: 19685701 Review. Hungarian.
Cited by
-
Lentiviral Hematopoietic Stem Cell Gene Therapy Corrects Murine Pompe Disease.Mol Ther Methods Clin Dev. 2020 May 4;17:1014-1025. doi: 10.1016/j.omtm.2020.04.023. eCollection 2020 Jun 12. Mol Ther Methods Clin Dev. 2020. PMID: 32462050 Free PMC article.
-
The Respiratory Phenotype of Pompe Disease Mouse Models.Int J Mol Sci. 2020 Mar 24;21(6):2256. doi: 10.3390/ijms21062256. Int J Mol Sci. 2020. PMID: 32214050 Free PMC article. Review.
-
Glycogenosome accumulation in the arrector pili muscle in Pompe disease.Orphanet J Rare Dis. 2014 Feb 5;9:17. doi: 10.1186/1750-1172-9-17. Orphanet J Rare Dis. 2014. PMID: 24495340 Free PMC article.
-
Temporal neuropathologic and behavioral phenotype of 6neo/6neo Pompe disease mice.J Neuropathol Exp Neurol. 2008 Aug;67(8):803-18. doi: 10.1097/NEN.0b013e3181815994. J Neuropathol Exp Neurol. 2008. PMID: 18648322 Free PMC article.
-
Non-muscle involvement in late-onset glycogenosis II.Acta Myol. 2013 Oct;32(2):91-4. Acta Myol. 2013. PMID: 24399865 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Molecular Biology Databases